Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody
Nov 14, 2016 13:01 pm UTC| Business
HAMPTON, N.J., Nov. 14, 2016 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data on new product candidate CDX-1140, a fully human antibody targeted to CD40 that has demonstrated potent agonist activity. Found on...
Energy Focus, Inc. Reports Third Quarter 2016 Results
Nov 14, 2016 13:01 pm UTC| Business
SOLON, Ohio, Nov. 14, 2016 -- Energy Focus, Inc. (NASDAQ:EFOI), a leader in LED lighting technologies, today announced financial results for the third quarter ended September 30, 2016. Third Quarter 2016 Financial...
Insmed to Participate at November Investor Conferences
Nov 14, 2016 13:01 pm UTC| Business
BRIDGEWATER, N.J., Nov. 14, 2016 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at...
Insmed to Participate at November Investor Conferences
Nov 14, 2016 13:01 pm UTC| Business
BRIDGEWATER, N.J., Nov. 14, 2016 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at...
Nov 14, 2016 13:01 pm UTC| Business
NEW YORK, Nov. 14, 2016 -- The Wall Street Journal today launched a redesigned newspaper, showcasing the most compelling daily package of business, economic and financial news, complimented by incisive features and...
Nov 14, 2016 13:01 pm UTC| Business
NEW YORK, Nov. 14, 2016 -- The Wall Street Journal today launched a redesigned newspaper, showcasing the most compelling daily package of business, economic and financial news, complimented by incisive features and...
Nov 14, 2016 13:01 pm UTC| Business
-- CB 2679d/ISU304 Demonstrates Beneficial Effect in Hemophilia B Murine Models Using Subcutaneous Dosing -- -- Subcutaneous Phase 1/2 Proof-of-Concept Clinical Trial of High-Potency Factor IX CB 2679d/ISU304 in...